| 14.3845 0.145 (1.01%) | 12-08 14:04 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 17.57 | 1-year : | 20.53 |
| Resists | First : | 15.05 | Second : | 17.57 |
| Pivot price | 12.26  |
|||
| Supports | First : | 11.63 | Second : | 9.52 |
| MAs | MA(5) : | 14.09 |
MA(20) : | 11.94 |
| MA(100) : | 9.54 |
MA(250) : | 0 | |
| MACD | MACD : | 1 |
Signal : | 0.7 |
| %K %D | K(14,3) : | 87.6 |
D(3) : | 88.2 |
| RSI | RSI(14): 69.1 |
|||
| 52-week | High : | 20.26 | Low : | 3.97 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ FTRE ] has closed below upper band by 18.1%. Bollinger Bands are 135.9% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 7 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 14.97 - 15.07 | 15.07 - 15.15 |
| Low: | 13.94 - 14.04 | 14.04 - 14.12 |
| Close: | 14.1 - 14.26 | 14.26 - 14.38 |
Fortrea Holdings Inc., a contract research organization, primarily engages in the provision of biopharmaceutical product and medical device development services worldwide. It operates through two segments: Clinical Services and Enabling Services. The Clinical Services segment provides across the clinical pharmacology and clinical development spectrum. The Enabling Services segment provides patient access and clinical trial technology solutions to customers that streamline complex randomization and optimize the trial drug supply process. The company offers delivery models that include full service, functional service provider, and hybrid service structures. It also offers phase I-IV clinical trial management, differentiated technology enabled trial solutions, and post approval services. The company serves pharmaceutical, biotechnology, and medical device organizations. Fortrea Holdings Inc. was incorporated in 2023 and is based in Durham, North Carolina.
Sun, 07 Dec 2025
Fortrea Holdings Inc. (NASDAQ:FTRE) Surges 27% Yet Its Low P/S Is No Reason For Excitement - simplywall.st
Fri, 05 Dec 2025
Fortrea (NASDAQ:FTRE) Stock Price Down 5.7% - Time to Sell? - MarketBeat
Fri, 05 Dec 2025
Fortrea Holdings Inc. (NASDAQ:FTRE) Receives Average Recommendation of "Hold" from Analysts - MarketBeat
Thu, 04 Dec 2025
Fortrea (FTRE) and SCTbio team up to speed cell and gene therapy development - Stock Titan
Thu, 04 Dec 2025
Capital Fund Management S.A. Grows Stake in Fortrea Holdings Inc. $FTRE - MarketBeat
Wed, 03 Dec 2025
Improved Revenues Required Before Fortrea Holdings Inc. (NASDAQ:FTRE) Stock's 26% Jump Looks Justified - 富途牛牛
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 92 (M) |
| Shares Float | 92 (M) |
| Held by Insiders | 0.5 (%) |
| Held by Institutions | 104.3 (%) |
| Shares Short | 10,410 (K) |
| Shares Short P.Month | 9,850 (K) |
| EPS | -11.36 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 6.3 |
| Profit Margin | -36.8 % |
| Operating Margin | -0.6 % |
| Return on Assets (ttm) | -1.4 % |
| Return on Equity (ttm) | -98.2 % |
| Qtrly Rev. Growth | 3.9 % |
| Gross Profit (p.s.) | 5.55 |
| Sales Per Share | 29.87 |
| EBITDA (p.s.) | 0.13 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 2 (M) |
| Levered Free Cash Flow | 135 (M) |
| PE Ratio | -1.27 |
| PEG Ratio | 0 |
| Price to Book value | 2.28 |
| Price to Sales | 0.48 |
| Price to Cash Flow | 886.73 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|